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Abstract
Vulvar squamous cell carcinoma (VSCC) is a rare female genital neoplasm. Although numerous molecular changes
have been reported in VSCC, biomarkers of clinical relevance are still lacking. On the other hand, there is emerging
evidence on the use of mtDNA as a diagnostic tool in oncology. In order to investigate mtDNA status in VSCC
patients, haplogroup distribution analysis and D-loop sequencing were performed. The results were compared with
available data for the general Polish population, cancer free-centenarians as well as patients with endometrial and
head and neck cancer. The obtained data were also compared with the current status of mitochondrial databases.
Significant differences in haplogroup distribution between VSCC cohort, general Polish population and cancer-free
centenarians cohort were found. Moreover, a correlation between the VSCC patients haplogroup and HPV status
was observed. Finally, a specific pattern of mtDNA polymorphisms was found in VSCC. Our results suggest that the
mitochondrial genetic background may influence the risk of VSCC occurrence as well as susceptibility to HPV
infection.
Introduction
Vulvar squamous cell carcinoma (VSCC) is a rare
female genital neoplasm - it is 2.5% of cancer cases
among women, and 5% of all gynecological cancers,
which is the 4
th ranking cause of morbidity - after
breast, cervix and endometrial carcinomas [1]. Today
two models of vulvar tumorigenesis are accepted: HPV-
associated pathway and HPV-independent pathway.
Unfortunately molecular data on VSCC are fragmentary
and incoherent [2,3].
Mitochondrial dysfunction has been linked to a wide
range of degenerative and metabolic diseases, cancer,
and aging with its genome (mtDNA) being considered
as “Pandora’s box” of pathogenic mutations and poly-
morphisms [4,5]. MtDNA has a very high mutation rate,
which results in three classes of clinically relevant phe-
notypes. Deleterious germline line mtDNA mutations
are linked to mitochondrial diseases, mtDNA poly-
morphisms are linked to environmental adaptation in
human evolution and mtDNA somatic mutations are
linked with aging and cancer [6,7]. Mitochondrial
defects were first associated with carcinogenesis several
decades ago, when Warburg reported ‘injury of the
respiratory chain’ and high glycolysis rate as typical of
cancer [8]. Until now the role of mitochondria in neo-
plasm formation is supported by a growing body of evi-
dence. Today mitochondrial dysfunction does appear to
be a factor in cancer etiology [9-12]. Alterations in the
mitochondrial genome (mtDNA), including point muta-
tions, deletions, insertions, and genome copy number
changes, are believed to be responsible for this phenom-
enon [13-17]. It is for the fact that mitochondria are
pivotal to cell metabolism, but also to regulating cellular
signal transduction pathways. It is now postulated that
reactive oxygen species (ROS) provide the interface
between the mtDNA mutations and cancer progression
[18-20].
Mutations have been found in cell lines and tumor-
derived samples. Reported mtDNA mutations and poly-
morphisms were shown to be localized in the entire
mitochondrial genome. Nevetheless the highest muta-
tion rate was reported for the displacement loop
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its two hypervariable regions: HV1 (nucleotides 16024-
16383) and HVII (57-372) [10,13,21,22]. High frequency
of mtDNA mutations have been reported in variety of
cancer types including: bladder, breast, colon, head and
neck, liver, lung, prostate, and thyroid cancer. MtDNA
alterations are also found in gynecological cancers.
Wang et al. analyzed 12 mtMSI (mitochondrial instabil-
ity) regions in cervical, endometrial and ovarian cancer
and found that 95.6% of alterations localized in the D-
loop [23]. In endometrial carcinoma the occurrence of
mtMSI in position 303-315 was shown to correlate with
an increased mtDNA content, when normal endome-
trium and tumor samples were compared [24]. More-
over, somatic mutations in the D-loop, 12 S rRNA and
16 S rRNA sequences were found to be frequent in this
type of cancer [25]. The inheritance of mtDNA with
haplogroup-D specific polymorphisms localized in the
D-loop was shown to increase the risk of endometrial
cancer development [26]. The D-loop and cytochrome b
gene (cytB) were shown to be mutated in 20% of ovarian
cancer cases [27]. We have previously shown that as
many as 57% of Polish ovarian cancer patients carry
somatic mutations in D-loop. Although mutations
reported in that study did not correlate with patients’
medical history, the mtDNA content in tumor samples
was significantly increased in comparison to control -
noncancerous ovarian tissue [28].
For several reasons mtDNA seems to be a good target
of clinical analyses [9,29,30]. MtDNA is present in thou-
sands of copies within the cell, therefore an infinitesimal
amount of the tissue is needed for successful analysis
and minimally-invasive procedures may be used to
obtain diagnostic material [31,32]. Moreover, mtDNA
alterations are easily detectible not only in the tumor
sample, but also in body fluids [33]. At the same time,
mtDNA mutation and polymorphism analyses are rela-
tively fast and cost-effective [34].
To our best knowledge until today no VSCC patients
has been performed. In our opinion, such an experiment
fills the gap in gynecological mitochondrial oncology. As
a first step to accomplish this goal we screened D-loop
of VSCC samples in order to identify somatic mutations
and a pattern of inherited polymorphisms Our step was
of specificity of haplogroup distribution among SC.
Finally, the last step of the study included correlation
analysis of molecular characteristics and patients’ medi-
cal history.
Materials and methods
Analyzed cases
Cancer cohorts
Tumor samples and control tissue form VSCC cases
were obtained in The Maria Sklodowska-Curie
Memorial Cancer Centre in Warsaw. The patients were
treated for VSCC under standard protocols between
2002 and 2006. Surgery was performed as described pre-
viously [35]. All patients enrolled in the study had histo-
pathologically confirmed invasive VSCC of (Table 1).
Apart from two patients with a history of ovarian cancer
stage III, patients had not previously been treated for
any malignancy. Altogether 25 paired tumor and blood
samples were investigated. In five cases the tumor mar-
gin was also available for analysis. Genomic DNA was
isolated from approximately 25 mg of each pulverised
with a Microdismembrator II (B Braun Biotech Interna-
tional) sample with a NucleoSpin Tissue kit (Macherey
Nagel Inc.) according to the manufacturer’sp r o t o c o l .
The presence and genotyping of HPV was performed
using Linear Array HPV Detection Kit and Linear Array
HPV Genotyping Test (Roche Molecular Systems, Inc)
as described previously [36].
The head and neck patients and endometrial adeno-
carcinoma patients were recruited as described pre-
viously [12,34].
Control cohorts
The DNA of 84 healthy centenarians was obtained from
the Polish Centenarians project DNA-bank localized in
The International Institute of Molecular and Cell Biol-
ogy in Warsaw. All centenarians had negative cancer
medical history and negative family history of cancer
[37].
General Polish population data was obtained from our
previous analysis [38] and the analysis performed by
Malyarchuk et al. [39].
Table 1 Clinical characteristics of the investigated group
of VSCC patients.
Parameter Number of cases
Age <55 1(4%)
>55 24(96%)
Tumor size T1 4(16%)
T2 17(68%)
T3 3(12%)
Metastasis M0 25 (100%)
M1 0 (0%)
Lymph node status N0 15 (60%)
N1 4 (16%)
N2 1 (4%)
NX 5 (20%)
HPV infection* positive 5 (21%)
16 3(12%)
58 1(4,%)
6 1(4%)
negative 19(79%)
*the HPV status of one of the patients was unknown
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nationality, parentage, descent and reside in Poland.
This study did not include any patients of Asian, Afri-
can-American or Jewish origin [34].
The mtDNA research project was approved by the
local Ethics Committee at the Medical University of
W a r s a w ,P o l a n d( K B - 0 / 6 / 2 0 0 7t oA M C ,a n dK B - 0 / 7 /
2007 to WK). The VSCC project was approved by the
local Ethics Committee of the Cancer Center at the
Institute of Oncology (44/2002 to JR). The centenarians’
project was approved by local Ethics Committee of the
Central Clinical Hospital of the Military Medical Acad-
emy (currently Military Medical Institute) in Warsaw.
The Centenarians Database was registered at the Bureau
of the Inspector General for the Protection of Personal
Data in May 1999.
Polymorphisms and mutations analysis
The mtDNA sequences were obtained from tumor,
blood and normal tissue (tumor margin) and aligned to
the revised Cambridge Reference Sequence (rCRS) and
sequence variants were recorded [40,41]. Germline
(inherited) polymorphism was defined as a difference
between normal tissue sequence and rCRS. Polymorph-
ism is present both in normal and tumor tissues of a
particular patient. Whenever the difference between
mtDNA sequences obtained from tumor sample and
normal tissue (blood or margin) occured, it was defined
as a somatic mtDNA mutation. All described mtDNA
alterations were plotted against data from mtDB (35)
and MITOPAP databases [41,42].
D-loop sequence analysis
D-loop region (mtDNA 16024-576) was amplified with
three overlapping pairs of primers (Table 2). Each of the
forward primers contained FM13 (TGTAAAAC-
GACGGCCATG) sequence at the 5’ site, and each of
the reverse primers contained RM13 (CAGAGGA-
CAGCTATGACC) tail at the 5’ site. PCR was carried
out in a MJ Research Dyad dual block thermocycler
(Bio-Rad) with the following cycling conditions: initial
incubation 3’at 95°C, followed by 30 cycles: (30” 95°C,
30” 55°C, 1’ 72) with a final extension step for 7’ at
72°C. Two microlitres of the PCR product were analyzed
on an ethidium bromide-stained 1.5% agarose gel (30’ 80
V) for quantification purposes. Sequencing reactions
were carried out at Oligo.pl
©.
The quality of the obtained chromatograms was
assessed in FinchTV® software version 1.4.0 (Geospiza
Inc., USA). All sequences were analyzed and corrected
manually when necessary. Subsequently chromatograms
were imported into Sequencher® 4.1.4 software (Gene
Codec Corporation, Ann Arbor, MI USA) and D-loop
contigs were assembled (minimal overlap 20 bp, 85% of
identity).
Haplotyping by RFLP and D-loop analysis
The patterns of specific polymorphisms in mtDNA
determine classes of related genotypes, referred to as
haplogroups (H, I, J, K, T, U, V, W, X; Table 3). The
mtDNA fragments containing polymorphic sites charac-
teristic for specific haplogroups were amplified by PCR
according to the following cycling conditions: initial
incubation for 3’ at 95°C, followed by 35 cycles (30”
95°C, 30” 55°C, 1’ 72) with a final extension step for 7’
at 72°C. One microlitre of PCR product was analyzed on
an ethidium bromide-stained 1.5% agarose gel (30’ 80 V)
and then digested by appropriate restriction enzymes
(overnight, 37°C). The digestion products were analyzed
on an ethidium bromide-stained 2.5% agarose gel (75’,
60 V). Tree diagram was used to facilitate haplogroup
analysis [43]. In addition to canonical loci (Table 3 -
positions 1-14), new RFLP reactions were designed for
the project and additional positions in mtDNA were
also investigated (Table 3 - positions 14-22) [41,43-45].
In addition to coding sequence analysis the D-loop
sequence was also analyzed in order to establish haplo-
type of each patient. The haplogroup assignment was
done as previously published [11,28]. Finally it was also
validated with mtDNA search engine [46].
Statistical analysis
Two tailed non-directional Fisher-Irwin (Fisher’s exact
test) was used for statistical analysis [47]. Statistical ana-
lysis was performed with PAST (PAlaeontological Statis-
tics) software ver. 1.34 (Øyvind Hammer, D.A.T. Harper
and P.D. Ryan, 2005) and Analyse-it for Microsoft Excel
General & Clinical Laboratory modules Version 1.73
(Analyse-it Software, Ltd. Copyright © 1997-2005). The
difference was considered statistically significant if p <
0.05. To confirm the result of Fisher’st e s t-Y a t e s ’sc h i
and un-corrected chi squared test (’N -1 ’ chi squared
test) were used to give relatively low Type I error in the
case of a small number of cases analyzed. The statistics
was performed as previously recommended by Campbell
[48]. To further calculate the significance of specific
polymorphisms as factors of favorable outcomes (odds
ratio, relative risk, difference in proportions, absolute
Table 2 Primers used in D-loop sequencing.
Primer name Primer sequence Position in mtDNA
FM13.D1F AATGGGCCTGTCCTTGTAG 15879-15897
RM13.D1R AACGTGTGGGCTATTTAGGC 16545-16526
FM13.D2F CGACATCTGGTTCCTACTTC 16495-16514
RM13.D2R GGGTTTGGTTGGTCCGGG 559-542
FM13.D3F CGCTTCTGGCCACAGCAC 315-332
RM13.D3R GGTGTGGCTAGGCTAAGC 803-786
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Haplogroup Polymorphism Enzyme Primer
F
Primer
R
Primer F - sequence Primer R - sequence PCR
product
RFLP DNA
fragments if
this
haplogroup
RFLP DNA
fragments if
not this
haplogroup
1 H C7028T Alu I 6730F 7398R CTATGATATCAATTGGCTTCC GGCATCCATATAGTCACTCC 669 342, 158,
139, 30
342, 188, 139
2 U/K A12308G Hinf1 11902F 12328R GCTAGTCCACGTTCTCCT TTTGGAGTTGCACCAAGAATT 427 162, 158,
59, 48
221, 158, 48
3 K G9055A HaeII 8563F 9231R ACAATCCTAGGCCTACCCG GATAGGCATGTGATTGGTGG 669 669 494, 175
4 I G16398A BamHI 15879F 16545R AATGGGCCTGTCCTTGTAG AACGTGTGGGCTATTTAGGC 667 511, 156 667
5 I T10031C Alu I 9821F 10516R ACTTCACGTCATTATTGGCTC ATGGAGATGGTAATTGCTAG 696 283, 209,
204
413, 283
6 I G8251A AvaII 7960F 8641R ATTATTCCTAGAACCAGGCG TGATGAGATATTTGGAGGTGG 682 392, 290 682
7 I A4529T HaeII 4184F 4869R TCCTACCACTCACCCTAGC GTCATGTGAGAAGAAGCA 686 686 350, 336
8 W G8994A HaeIII 8563F 9231R ACAATCCTAGGCCTACCCG GATAGGCATGTGATTGGTGG 669 266, 205,
187, 11
266, 205, 156,
31, 11
9 T A15607G AluI 15372F 16067R TAGGAATCACCTCCCATTCC GTCAATACTTGGGTGGTACC 696 236, 218,
170, 72
406, 218, 72
10 T G13368A BamHI 12951F 13614F CGCTAATCCAAGCCTCACC TATTCGAGTGCTATAGGCGC 691 691 416, 248
11 J G13708A BstNI 13568F 14276R TTACTCTCATCGCTACCTCC GGTTGATTCGGGAGGATCC 709 709 571, 138
12 J C16069T Hinf1 15879F 16545R AATGGGCCTGTCCTTGTAG AACGTGTGGGCTATTTAGGC 667 480, 122, 65 602, 65
13 V G4580A NlaIII 4184F 4869R TCCTACCACTCACCCTAGC GTCATGTGAGAAGAAGCA 686 684, 2 397, 287, 2
14 X G1719A DdeI 1138F 1801R GAACACTACGAGCCACAGC TCATCTTTCCCTTGCGGTAC 664 188, 187,
134, 111,
30, 14
188, 187, 111,
86, 48, 30, 14
15 W1 A11947G BsmFI 11765F 12108R GCACTCACAGTCGCATCATAA TTGAGGGATAGGAGGAGAATG 343 196, 149 343
16 M C10400T AluI 10381F* 10671R AAAAAGGATTAGACTGAGCTGA CGGCAAAGACTAGTATGGCAA 318 201, 172, 18 219, 72
17 J, T, L2, H T4216C NlaIII 4142F 4379R GATTCCGCTACGACCAACTC GCACGGAGAATTTTGGATTC 197 160, 78 197
18 HV C14766T MseI 14642F 14968R CCCACACTCAACAGAAACAAA AGCGGATGATTCAGCCATAA 346 203, 142, 4 203, 125, 17, 4
19 U/K A1811G PsiI 1623F 1909R GCACCCAACTTACACTTAGGA TTTCGGGGGTCTTAGCTTT 287 287 188, 101
20 K A10550G NlaIII 10387F 10761R GATTAGACTGAACCGAATTGG CGGCAAAGACTAGTATGGCAA 285 164, 121 285
21 T A4917G BfaI 4865F 5192R ATGACAAAAACTAGCCCCCA AGGGTGGATGGAATTAAGGGT 348 298, 39, 11 337, 11
22 X T6221C Mnl I 5881F 6254R* GCCATTTTACCTCACCCCCACTGATGTTCG TATAGCAGATGCGAGCAGGAGTAGGAGATAGGGA 374 131, 115,
108, 20
115, 108, 106,
25, 20
Restriction enzymes and primers used indicated. * mismatched primers.
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5and relative reduction in risk) and the effectiveness of a
diagnostic criterion (number needed to diagnose, specifi-
city, positive and negative predictive values, positive and
negative likelihood ratios, diagnostic and error odds
ratios) additional analyses have been performed. These
parameters, as well as the confidence intervals for the
estimated parameters were computed by general meth-
ods [49,50].
Results
Haplogroup analysis
Haplogroup distribution in the group of 25 VSCC
p a t i e n t si ss h o w ni nF i g u r e1 A :s e v e np a t i e n t s( 2 7 % )
belong to haplogroup H, eight (32%) to haplogroup U,
three (12%) to K and T, two (9%) to W, and one (4%) to
haplogroup J. One patient (4%) could not be classified to
any investigated European haplogroup, due to unspecific
polymorphisms pattern. Haplogroup assessment with
the mtDNA search engine [46] revealed that this patient
probably harbors mtDNA polymorphisms characteristic
for East Asian haplogroup Y1b, which suggested other
than Polish descent [51]. No patients were found to be
classified haplogroup I, V and × members. As expected
[44,52], no patient showed a positive RFLP pattern for
haplogroup M.
In order to verify haplogroup distribution in the VSCC
cohort differs from that of the healthy Polish population
and whether any similarities to the other cancer com-
parisons were made: 1. with general Polish population
(PP and NP) [38,39], 2. with cancer-free centenarians
(CENT), 3. with head and neck cancer (HNC) 4. with
endometrial adenocarcinoma cohort (EA) [53] (Tables 4
and 5). First of all, the underrepresentation of hap-
logroup H in the VSCC cohort was found. In other
words haplogroup H was overrepresented in healthy
individuals (cancer free centenarians - CENT). More-
over, in the comparison with the combined general Pol-
ish population (COMB), a trend towards haplogroup U
overrepresentation was also noticed. A trend for hap-
logroup K overrepresentation was also found. When
further comparison of super-haplogroup UK (encom-
passing haplogroup U1-U7 and haplogroup K) frequency
was made (Table 6), its overrepresentation in VSCC
patients became highly sig n i f i c a n t( 4 4v s .1 9 % ,p=
0.009). Finally, a comparison with cancer free centenar-
ians shows a trend of overrepresentation of haplogroup
W in the VSCC cohort (Table 4, Figure 1A and 1B). As
expected, the distribution of haplogroups in VSCC is
similar to other studied cancer groups (HNC and EA).
The underrepresentation of haplogroup H in the
VSCC cohort was particularly interesting. Haplogroup H
is marked by T7028C polymorphism. Therefore, if hap-
logroup H is underrepresented in the VSCC cohort,
7028T polymorphism is overrepresented. This suggests
that a positive RFLP test (7028T) may indicate an
increased susceptibility to VSCC. In order to check the
properties of this RFLP test additional analyses were
performed. VSCC harbour 7028C in 28% of cases, while
centenarians carry single nucleotide polymorphism
(SNP) 7028C in 55% cases. The difference is significant
at p = 0.023 with Fisher’s exact test. This significance is
further confirmed with Yates corrected chi square test,
with c
2= 4.50 and p = 0.034, but also with ‘N-1’ chi
square test, with c
2 = ‘N-1’ and chi square = 5.47 and
p = 0.02. he 7028T test has Odds Ratio (OR) and Diag-
nostic Odds Ratio = 3.11 and indicates Relative Risk
(RR) = 2.43 in comparison to cancer free centenarians.
Figure 1 Haplogroup distribution in the studied group of VSCC
patients (A) and haplogroup distribution in control
populations: cancer free centenarians - (B) and head and neck
cancer patients (C).
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Needed to Diagnose (NND) is 3.73. The Positive Predic-
tive Value (PPV) of the test is 0.32 at sensitivity 0.72,
while the negative predictive value (NPV) is 0.67 and
relative risk reduction (RRR) is 0.59.
Sequencing data analysis
Germ-line polymorphisms in the mtDNA D-loop region in
VSCC
Altogether 25 paired mtDNA D-loop sequences from
both tumor and blood samples were sequenced. The
results are summarized in Table 7. The group of VSCC
patients is characterized by 78 germ-line polymorphism
(differences haplogroup H - rCRS) [40]. In particular 19
out of 78 polymorphisms are generally uncommon [42]
and one polymorphism had not been reported pre-
viously (C498delC). Polymorphisms were predominantly
found in mtDNA hypervariable regions HV1 (16024-
16383) and HV2 (57-333) - 42/78 (54%) and 23/78
(29.5%) polymorphisms, respectively (Table 7, Figure 2A
and 2B). Eight (10%) SNPs were localized in HV3 (438-
574). The analysis of the control region haplogroup spe-
cific loci revealed significant overabundance of certain
polymorphisms in the investigated VSCC group of
patients. These overrepresented polymorphisms include
C16192T, C16256T and C16270T, all being specific for
haplogroup U, which is in accordance with the trend
observed by haplogroup comparison (Table 6 and Figure
1). The other overrepresented SNPs include 195C, 259G,
477C, 498delC, 533C, 16092G, 16189A, 16248T,
16272G, 16362C. The 16223T sequence variant, charac-
teristic for haplogroups I, W and X, was underrepre-
sented in the VSCC cohort, again reflecting the
haplogroup distribution trend. All those results suggest
that specific polymorphisms may be found in VSCC.
These polymorphisms include not only haplogroup-spe-
cific polymorphisms (Figure 1.), but also D-loop poly-
morphisms (Table 7). No somatic mutations were found.
Table 4 Analysis of the specificity of haplogroup distribution in VSCC cohort.
12 3 4 5 6
Positive Negative % positive p vs PP p vs NP p vs COMB p vs CENT p vs HNC p vs EA
H 7 18 28% 0.502 0.102 0.152 0.023 U 0.39 0.173
I 0 25 0% 1 1 1 0.194 1 1
J 1 24 4% 0.697 0.7 0.712 1 1 0.191
K 3 22 12% 0.381 0.067 0.092 0.693 0.333 1
NN 1 24 4% 1 0.547 0.552 ND 0.613 0.61
T 3 22 12% 1 1 1 0.712 1 0.668
U 8 17 32% 0.3 0.052 0.104 0.01 O 0.761 0.764
V 0 25 0% 0.368 0.385 0.389 1 1 1
W 2 23 8% 0.147 0.254 0.209 0.051 0.218 1
X 02 5 0 %11 1 1 1 1
Total 25
Haplogroup distribution in VSCC patients cohort was were compared with 1) the general Polish population (p vs PP) [38], 2) population from the Northern
Poland (p vs NP) [39], 3) those two populations combined (p vs COMB), 4) cancer free centenarians cohort (p vs CENT), 5) head and neck tumors patients cohort
(p vs HNC), and 6) endometrial adenocarcinoma patients cohort (p vs EA) [11]. % positive - percentage of patients carrying particular haplotype in VSCC cohort.
Significant differences - bolded: O - overrepresented in VSCC cohort, U - underrepresented in VSCC cohort.
Table 5 Analysis of the specificity of haplogroup
distribution HNC cohort.
12 3 4 6
% positive p vs PP p vs NP p vs COMB p vs CENT p vs EA
H 0.43 0.67 0.847 1 0.286 0.015
I 0 1 1 1 0.197 1
J 0.07 1 1 1 1 0.243
K 0.04 1 1 1 0.677 0.184
NN 0.11 0.11 0.065 0.065 ND 1
T 0.11 1 1 1 1 1
U 0.25 0.62 0.29 0.31 0.053 1
V 0 0.22 0.629 0.389 1 1
W 0 1 0.614 1 1 0.227
X 01 1 1 11
Haplogroup distribution in VSCC patients cohort was were compared with 1)
the general Polish population (p vs PP) [38], 2) population from the Northern
Poland (p vs NP) [39], 3) those two populations combined (p vs COMB), 4)
cancer free centenarians cohort (p vs CENT), 5) head and neck tumors
patients cohort (p vs HNC), and 6) endometrial adenocarcinoma patients
cohort (p vs EA) [11]. % positive - percentage of patients carrying particular
haplotype in VSCC cohort. Significant differences - bolded: O -
overrepresented in VSCC cohort, U - underrepresented in VSCC cohort.
Table 6 Comparison of UK super-haplogroup frequency
between VSCC and 1) the general Polish population [38],
2) population from Northern Poland [39], and 3) those
two populations combined.
12 3
p vs PP p vs NP p vs COMB
Fisher two-tailed 0.099 0.009 0.000
Fisher L 0.973 0.998 1.000
Fisher R 0.070 0.006 0.000
Significant differences - bolded.
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mtDNA
position
(rCRS)
Polymorphism Case No No A/G/C/T/
del
frequency
mtDB
Tissue where sequence
was found
P-
value
Region/population where
sequence variant
predominantly found
73 A > G 15,16,17,25, 26,27,29,30,
38,40,41,42,
45,46,49,50,51
17 309/1555/
1/0/0
pancreatic cancer,
thyroid tumor,
oral cancer aging
brains, POLG/PEO &
control muscle,
0.056 Very common
93 A > G 27 1 1824/41/
0/0/0
ovarian cancer 0.432 Japan Finland,
Italy India
97 G > A 33 1 Nd Polymorphism - Nd
103 GCC > DEL
GCC
33 1 Nd oral cancer -N d
111 A > C 33 1 Nd Polymorhism - Nd
146 T > C 15,33,49,51 4 1/0/190/
1674/0
prostate tumor, ovarian
carcinoma elderly
fibroblasts, aging/AD
brains,
POLG/PEO & control
muscle,
0.316 Africa, Japan, Taiwan,
Finland, Italy, Spain,
Algerian Jew, India,
Polynesia, Caucasi
150 C > T 16,41,50 3 0/2/1616/
247/0
lung tumor,
thyroid tumor elderly
fibroblasts/leukocytes
1 China, Japan, Berbers, Italy
151 C > T 16 1 0/0/1817/
48/0
Polymorphism 0.484 Japan, Finland, Sweden,
India
152 T > C 13,26,33,49 4 0/0/396/
1469/0
pancreatic cancer,
ovarian carcinoma, oral
cancer
aging brains, elderly
fibroblasts,
0.803 Africa, China, Japan,
American, Finland, Italy
189 A > G 26,29 2 1782/75/
8/0/0
prostate tumor elderly
muscle, POLG/PEO
muscle
& fibroblasts, aging
brains
0.271 Japan, Finland, India
194 C > T 26,29 2 0/0/1797/
68/0
POLG/PEO muscle 0.236 Japan, Indian
195 T > C 26,29,39,42, 44, 46,50 8 11/0/280/
1574/0
lung-cancer cells,
thyroid tumor,
oral cancer
elderly fibroblasts,
aging/AD brains,
0.042
O
Africa, Japan, American,
Finland, Italy, Caucasian
199 T > C 29 1 0/0/121/
1741
ovarian cancer,
POLG/MNGIE muscle
1.000 Japan, Finland, India
204 T > C 26,29 2 0/0/123/
1741/0
oral cancer,
prostate tumor
0.679 Japan, Finland, India
207 G > A 26,29 2 123/1742/
0/0/0
oral cancer, prostate
tumor,thyroid tumor
0.679 Japan, Finland, India
242 C > T 15 1 0/0/1854/
11/0
POLG/PEO muscle 0.148 Extremely rare, American,
Finland
259 A > G 40 1 1866/1/0/
0/0
Liver cancer 0.026
O
Extremely rare, Thaiwan
263 A > G 13,15,16,17,
18,22,25,26,
27,28,29,30,
33,34,38,39,
40,41,42,44,45,46,49,50,51
25 6/1861/0/
0/0
oral cancer POLG/
MNGIE muscle,
1.000 Africa, Japan, China,
Australia, American,
Finland, India
285 C > T 46 1 0/0/1860/
7/0
elderly fibroblasts 0.101 Extremely rare, Italy, India
295 C > T 15 1 4/0/1788/
75/0
Glioblastoma,POLG/
MNGIE muscle
1.000 American, Finland, India,
Caucasian
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Page 7 of 15Table 7: Germ-line polymorphisms in the D-loop sequence of VSCC patients. (Continued)
303 C7 > C8 ins 16,17,26,28,29,30,38,39,40,41,42,45,51 13 - multiple tumor types Africa, Japan, Taiwan,
Finland, Italy, Spain, India,
Polynesia, Caucasian,
Ashkenazi Jew, American,
Australia
303 C7 > C9
Ins
18 1 - multiple tumor types Africa, Japan, Taiwan,
Finland, Italy, Spain, India,
Polynesia, Caucasian,
Ashkenazi Jew, American,
Australia
311 C5 > C6
Ins
13,15,16,17,
18,22,25,26,
27,28,29,30,
33,34,38,39,40,41,42,44,45,46,49,50,51
25 - multiple tumor types Africa, Japan, Taiwan,
Finland, Italy, Spain, India,
Polynesia, Caucasian,
Ashkenazi Jew, American,
Australia
385 A > G 46 1 1861/5/0/
1/0
Twinkle/PEO frontal
cortex
0.077 Extremely rare, Koraga
431 C > T 39 1 1/0/1852/
14/0
ovarian cancer 0.181 Rare,Japan
462 C > T 15 1 0/0/2073/
71/0
thyroid tumor 0.572 American, Finland, India,
Caucasian
477 T > C 13,34 2 0/1/19/
2124/0
ovarian tumor
AD brains
0.023
O
Rare, American, European
489 T > C 15 1 0/0/777/
1367
ovarian carcinoma
prostate tumor
0.000
U
Africa, China, Japan,
American, Finland, Italy,
India
498* C > del C 49 1 0/0/2143/
1/0
0.023
O
Extremely rare
499 G>A 5 0 1 38/2106/
0/0/0
thyroid tumor prostate
tumors
0.366 Japan
514 CA5 > CA4 25,39,41,44, 46 5 - ovarian carcinoma,
thyroid tumors,
gastric carcinomas
-N d
514 CA5 > CA6 29,49, 2 - ovarian carcinoma &
control tissue,
thyroid tumors, breast
tumors
-N d
533 A > G 16 1 2142/2/0/
0/0
Polymorphism 0.034
O
Extremely rare,
Japan, Sicily
16069 C > T 15 1 0/0/1793/
73/0
oral cancer 1.000 American, Caucasian,
Finland, Italy
16092 T > C 15,16,39 3 0/0/22/
1845/0
oral cancer 0.004
O
Extremely rare, Japan, India
16114 C>A 4 5 1 8/0/1858/
1/0
Polymorphism 0.113 Extremely rare, Japan,
Finland
16124 T > C 29 1 0/0/9/1858 Polymorphism 0.125 Extremely rare,South Africa,
Korea
16126 T > C 15,17,25,42,51 5 0/0/166/
1701/0
oral cancer 0.069 China, Japan, American,
Finland, Italy, India
16129 G>A 3 3 1 304/1554/
9/0/0
oral cancer 0.164 Arica, Japan, America, Italy
16145 G>A 1 5 1 50/1817/
0/0/0
oral cancer 0.497 Japan, American, Finland,
Italy
16172 T > C 15 1 0/0/150/
1717/0
head/neck tumor
back-mutation, oral
cancer MNGIE tissues,
0.716 Japan, Morocco, Finland,
Europe
16179 C > T 50 1 0/0/1862/
5/0
Polymorphism 0.077 Asia, Austrlia
16182 A > C 22,41,42,46 4 1706/1/
117/2/41
prostate tumor 0.071 China, Japan, Finland,
Taiwan Aborigine, India
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Page 8 of 15Table 7: Germ-line polymorphisms in the D-loop sequence of VSCC patients. (Continued)
16183 A > C 41,42 2 1541/12/
237/0/77
lung tumor back-
mutation, prostate
tumor
0.761 China, Japan, Finland,
Taiwan Aborigine, India
16189 T > A 39 1 0/0/522/
1345/0
Polymorphism 0.013
O
Extremely rare
16189 T > CC 22 1 - endometrial tumor,
familial breast
cancer
16189 T > C 41,45,42,46 4 0/0/522/
1345/0
endometrial tumor,
familial breast
caner
0.261
16192 C > T 16,27,29,38,
40,45
6 0/0/1854/
13/0
oral cancer 0.000
O
Japan, Finland, Italy
16222 C > T 15 1 0/0/1852/
15/0
oral cancer 0.192 American,
16223 C > T 26,29 2 0/0/992/
875/0
oral cancer 0.000
U
Africa, Japan, China,
Australia, India, Finland,
Ashkenazi Jews
16224 T > C 33,49 2 0/0/107/
1760/0
oral cancer 0.652 Japan, American, Finland,
Ashkenazi Jews
16231 T > C 51 1 0/0/11/
1856/0
oral cancer 0.148 Extremely rare, Japan
16234 C > T 26 1 0/0/1800/
67/0
oral cancer 0.602 China, Japan, Ashkenazi
Jews
16248 C > T 51 1 0/0/1865/
2/0
ovarian tumor 0.039
O
Extremely rare,
Spain, India
16249 T > C 46 1 0/0/87/
1780/0
prostate tumor 1.000 Ethiopia, Japan, Italy
16256 C > T 27,38,40,45 4 0/0/1838/
29/0
ovarian tumor 0.001
O
Japan, Finland, India
16261 C > T 15 1 0/0/1756/
111/0
oral cancer 1.000 Japan,Taiwan Aborigine,
American, India
16266 C > T 52 1 9/4/1820/
34/0
oral cancer 0.375 Japan, India
16270 C > T 16,27,38,40,41,45 6 0/0/1802/
65/0
oral cancer 0.000
O
Finland, Italy, India
16272 A > G 25 1 1865/2/0/
0/0
Polymorphism 0.039
O
Extremely rare Taiwan
Aborigine, India
16291 C > T 38 1 0/3/1816/
48/0
0.483 Japan, Italy
16292 C > T 26,29 2 0/2/1801/
64/0
breast, ovarian, head/
neck tumor,
oral tumor
0.216 Japan, Finland, Italy
16293 A > G 39 1 1848/17/
2/0/0
glioblastoma 0.214 Rare, Italy, India
16294 C > T 17,25,45 3 0/0/1760/
107/0
- 1.000 Japan, American, Finland,
Italy
16296 C > T 17,25 2 0/0/1823/
44/0
head/neck tumor 0.122 American, Italy, India
16298 T > C 42 1 0/0/169/
1698/0
oral cancer
prostate tumor
0.721 China, Japan, Finland,
American
16300 A > G 29 1 1861/6/0/
0/0
head/neck tumor 0.089 Extremely rare,
Japan
16301 C > T 39 1 0/0/1860/
7/0
esophageal, breast &
prostate tumors
0.101 Extremely rare Melanesia
16304 T > C 25 1 0/0/140/
1727/0
esophageal, breast &
prostate tumors
1.000 Japan, American, Finland,
Italy
16311 T > C 33,39,49 3 0/0/340/
1526/0
oral cancer 0.602 Africa, Japan, China,
American, Finland, Italy,
India
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VSCC cohort
The segments adjacent to the D-loop sequence (15879-
803, Table 8) were also analyzed. Two polymorphisms
were found within the 12 S rRNA gene, with the fre-
quency characteristic for the world population [42].
mtDNA D-loop sequence analysis in the tumor margin
In the case of five patients (13, 38, 45, 46, 49), tumor
margin samples were also available. Comparison of the
D-loop sequence from the sample triplets (tumor, blood
and margin) revealed no difference between these tis-
sues in all the investigated cases, again indicating the
presence of inherited polymorphisms and lack of
somatic mutations.
Correlation with clinical parameters
As the polymorphisms are inherited phenomena, no
correlation with TNM or clinical stage was performed.
However, an interesting co-incidence of HPV infection
with the specific mitochondrial haplogroup was
observed. Four out of five patients with HPV infection
carried haplogroup H. When taking into account only
high risk HPV-16, all infected patients belonged to this
haplogroup. The correlation between these two para-
meters was shown to be statistically significant (Table
9). This correlation is further supported by the very
similar haplogroup distribution found in the head and
neck tumors, that are also HPV-dependent (Figure 2C).
Discussion
Although several molecular alterations on the genomic,
genetic, epigenetic and protein level have been described
in VSCC, no useful molecular markers with possible
clinical application have been established so far [28].
Analysis of the mitochondrial genome may provide
novel cancer biomarkers for the risk assessment, diagno-
sis and prognosis. Mitochondrial DNA polymorphisms
and/or mutations are commonly used as molecular mar-
kers in a wide range of disciplines, from human migra-
tion and population studies, to metabolic diseases, and
may also prove useful in VSCC management [54].
mtDNA analysis is attractive due to its relatively low
cost and lack of requirement for sophisticated technical
support, thus making it accessible for most hospital
laboratories [10,55,56].
To the best knowledge of the authors, this the first
report on mtDNA status in VSCC patients. The analysis
of haplogroup distribution revealed a trend toward hap-
logroup U and K overrepresentation, haplogroup H
underrepresentation as well as super-haplogroup UK
overabundance in a group of VSCC patients in compari-
son with a large Polish control population, VSCC. These
data suggest that mitochondrial genetic background may
be related to an increased risk of VSCC incidence. The
inheritance of haplogroup U was previously associated
with increased risk of prostate cancer and renal cancer
in white North American individuals [32,57]. Hap-
logroup K was also shown to increase the risk of breast
cancer development among European-American women
[58], whereas haplogroup U decreased the risk of this
condition. The UK super-haplogroup has been hypothe-
sized to confer less coupling efficiency of ETC, thus
generating less ROS than other haplogroups (H, J and
T), and would be expected rather to have a protective
effect on cell damage. This hypothesis is supported by
association with increased b r a i np Hi np a t i e n t sw i t h
Table 7: Germ-line polymorphisms in the D-loop sequence of VSCC patients. (Continued)
16324 T > C 17 1 0/0/49/
1818/0
esophageal cancer 0.490 Japan, Taiwan Aborigine
16325 T > C 29 1 0/0/47/
1820/0
Polymorphism 0.476 Japan, India
16356 T > C 22,50, 2 0/0/27/
1840/0
oral cancer 0.055 India, Australian,
Aboriginee
16362 T > C 46 1 1/0/444/
1422
oral cancer 0.016
O
India, Australian,
Aboriginee
16368 T > C 49 1 0/0/15/
1852/0
gastric carcinoma 0.192 Extremely rare,
Japan, Italy
16399 A > G 38,40, 2 1828/38/
0/0/0
gastric carcinoma
oral cancer
0.096 Japan, Italy
16519 T > C 13,17,18,22,25,26,28,29,33,34,41,42,49,50,51 15 0/0/1115/
752/0
pancreatic, cancer,oral
cancer, gastric, lung,
ovarian
tumor
1.000 Africa, Japan, Caucasian,
China, American, Finland,
Italy, India
16526 G > A 45 1 19/1848/0/
0/0
Polymorphism 0.235 Finland, Onge
total 225
Unless stated otherwise, the data are from MITOMAP [63] and mtDB [42] databases.
*-previously not reported, O-overrepresented, U-underrepresented; over and under-represented polymorphisms bolded.
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Page 10 of 15psychiatric disorders [59] and decreased risk of Parkin-
son disease in individuals with this haplogroup [60].
However, the functional role of genetic background con-
ferred by UK super-haplogroup in cancer has not been
investigated. To fully assess the value of the observed
effect in the Polish population, a comparison of the
observed haplogroup frequencies with mtDNA variant
distribution in the healthy population with matched sex,
age and ethnicity as well as the study on a larger patient
cohort is needed [34,61].
The second part of our study was focused on the
D-loop sequence analysis in VSCC, as it has been
previously found to be altered in gynecological cancers
[10,13,15,23,32]. mtDNA polymorphisms characteristic
for the VSCC patients were identified. Some of those
polymorphisms are located in functionally important
regions of the D-loop. The mitochondrial control region
contains several elements essential for mtDNA replica-
tion and transcription. Sequence variants in this region
may affect binding affinity of trans-acting factors, result-
ing in an altered rate of mitochondrial replication and
transcription. Both increased and decreased mtDNA
copy number have been found in several types of cancer
[21]. Moreover, the polycytidine tract at nucleotide
positions 303-315 was highly polymorphic in all investi-
gated VSCC patients. This region is part of CSB II
(299-315) that is essential for proper primer formation
[62]. In previous studies an in vitro assay approach has
shown that premature termination of transcription
occurs immediately downstream to CSBII at positions
300-282, which is the site of the RNA-DNA transition
point. Premature termination was abolished in 319-289
mutants, whereas mutation at nucleotide positions 304-
300 showed a drastic decrease of this process [62], indi-
cating an important role of these sequence variants in
the transcription/replication switch. Moreover, the
screen of human mtDNA control sequence variants
revealed that the variant defining haplogroup J - C295T
increased TFAM protein binding and in vitro L-strand
transcription. Cybrid-based analysis of this variant
demonstrated an increased copy number (2 times,
J >H), but there was no difference in transcript levels.
This fact provides strong support for functional impor-
tance of mtDNA control region variants, additionally
underlying the role of haplogroup-defining mutations
within the D-loop [29]. This variant was also found in
the VC patient population. The other polymorphisms
localized within mtTFAM binding sites found in the
investigated cohort are G259A, C285T, C431T, A533G
and mtMSI at np 514-523. These variants may possibly
affect DNA-protein interactions. SNP 259A is extremely
rare [42]. According to data in MITOMAP, it was also
found in liver cancer, but this observation was unpub-
lished [63].
Figure 2 D-loop polymorphism distribution in the studied
group of VSCC patients 0 - 700 mtDNA bp (A) 16000 - 16659
bp mtDNA (B). × axis - mtDNA position (bp) - polymorphism
location. Y axis - number of cases found in this study -
polymorphism number.
Table 8 Polymorphisms found in the coding region of mtDNA of VSCC patients.
mtDNA
position
(rCRS)
Polymorphism Case No No A/G/C/T/del
frequency mtDB
P-
value
Region/population where sequence variant
predominantly found
709
12 S
rRNA
G > A 17,25,26,29,33,
41,42,46
8 444/2260/0 0.053 Africa, native Americans, Japan, American,
Finland, Italy, India
750
12 S
rRNA
A > G 13,15,16,17,18,22,25,26,27,28,29,30,33,34,
38,39,40,41,42,44,45,46,49,50,51
25 22/2682/0/0 1.000 CRS is a rare variant; G is very common in the
whole world, A/G is consensus mutation
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patients are at nucleotide positions 514-523. These poly-
morphisms are carried by seven VSCC patients. The
clinical significance of 514-523 polymorphisms as bio-
markers was proved in a study on breast cancer: patients
with multiple alleles of (CA) polymorphism (showing
heteroplasmy) had poorer survival in comparison to
patients with a homoplasmic (CA) variant, thus suggest-
ing the role of this dinucleotide repeat in cancer forma-
tion [64]. Moreover, our analysis of the D-loop
sequence also revealed that three polymorphisms char-
acteristic for haplogroup U (C16192T, C16256T and
C16270T) as well asC16223C polymorphism are signifi-
cantly overrepresented in the investigated group of
patients. They are all located within HV1 region.
16192T is found within microsatellite (16184-16193)
and was found to be a hot spot for mutations in several
types of cancer [23]. This sequence variant may be
important as it co-localizes with the 3’ end of TAS and
with the 7 S DNA binding site that are hypothesized to
play a role in mtDNA synthesis [65]. Moreover, the
T16189C variant was associated with an increased sus-
ceptibility to endometrial carcinoma in Chinese women
[66]. The 16223C SNP was also found at a significantly
higher frequency in VSCC patients compared with the
normal population, which is in similar to the data
obtained in our laboratory for endometrial carcinoma
[11]. Furthermore, the T195C variant, overabundant in
VSCC patients, was previously reported in lung [33] and
thyroid cancer [67], as well as in brains of Alzheimer
patients [68]. The exact role of T195C, C16223C,
C16256T and C16270T is unknown. It should be noted
that, as there are only a few observations for each poly-
morphism, the power to detect whether these SNPs play
a role in VSCC incidence is relatively low and research
performed on larger number of patients is needed. How-
ever, the obtained results strongly suggest a role for all
these polymorphisms in conferring genetic susceptibility
to VSCC development; and they appear to be attractive
biomarkers of VSCC risk assessment.
In VSCC patients no somatic mutations were detected,
which is in contradiction with several previous studies for
other cancer types [21]. It may be claimed that blood is
not a proper reference tissue, as mitochondrial mutations
were also found in body fluids [33]. However, this should
not be the case in the investigated cohort of patients, as
none of the patients showed distant metastases, and vulvar
tumor expansion occurs through the lymphatic system
[69]. In addition, D-loop sequence from tumor margin
also showed no alterations. Lack of somatic mutations in
cancer samples is similar to previous study finding only
polymorphisms in the samples of colon cancer [70]. There
a r ea l s od a t ap r o v i n gt h eh y p othesis that mtDNA poly-
morphisms are significantly associated with cancer devel-
opment [26,71]. Several studies report low mutation rate
and an abundance of mtDNA polymorphisms in cancer
samples [72]. Moreover, recent re-analyses of somatic
tumor-specific alterations revealed that most of them are
in fact sequence variants commonly found in the general
population [73-77]. Furthermore, a critical review of
mtDNA mutations reported in numerous papers sug-
gested that many of them were actually artifacts generated
by methodological and technical errors, and that a lot of
somatic and “novel” germline alterations seem thus to
result simply from improper sample management and
data analysis [78].
Another important topic of mtDNA studies in gyneco-
logical oncology is correlation of clinic-pathological
characteristics with molecular markers. Due to the fact
that only the germline polymorphisms were found, no
correlation with TNM parameters was assessed. Inter-
estingly, all three patients with the high risk HPV sub-
type 16 had haplogroup H. When analyzing all infected
patients, the statistically significant overrepresentation of
haplogroup H was still present. There is no literature
data on any correlation between the mitochondrial hap-
logroup and HPV infection, but some information from
research on cervical cancer is available, however, only
papers focusing on the influence of HPV on mtDNA
damage have been published to date. In the study of
Sharma et al., a correlation between mtDNA mutations
and HPV infection was found [79]. However, it cannot
be concluded from the report whether the mutations
were somatic or germline, as DNA sequences from
tumors of patients were compared to the MITOMAP
database, not to any control tissue. In another study on
cervical cancer, HPV positive tumors were found to
contain an increased number of somatic mutations (in
comparison to precancerous stages). On the other hand,
haplogroup H turned out to be highly protective against
AIDS progression [80], implying that mitochondrial
b a c k g r o u n dm i g h tp l a yar o l ei nt h ec o u r s eo fv i r u s -
related diseases. The result obtained for the VSCC
cohort suggests that haplotype may confer genetic sus-
ceptibility towards HPV infection. To confirm the rela-
tion of these two parameters, a study on a larger group
of patients is necessary.
Table 9 HPV infection status and haplogroup co-
incidence in VSCC patients.
HPV
total
HPV
16
+-total p-value +-total p-value
Haplogroup H + 4 3 7 p = 0.014 3 4 7 p = 0.017
- 1 16 17 0 17 17
total 5 19 24* 3 21 24*
*- 24 patients were included in the analysis, as in one case the HPV unknown.
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of mtDNA polymorphisms in modifying the risk of this
type of cancer incidence and opens new perspectives in
search for novel VSCC molecular markers. Therefore, it
seems plausible that mtDNA analysis (possibly com-
bined with other molecular markers) may help to iden-
tify individuals at risk of developing VSCC. The
mitochondrial genetic background is also likely to play a
role in predisposition to HPV infection, creating a hope
for the establishment of a novel molecular diagnostic
tool. However, to fully evaluate the prognostic potential
of the discovered alterations, investigation of a more
representative patient group is necessary. Such research
should include, in addition to the information on
mtDNA status, also data about other molecular altera-
tions found within the tumor, thus allowing a broader
perspective for an assessment of the role of mtDNA in
tumorigenesis. It should be noted that our study
includes only the data obtained from the sequencing of
the D-loop region. In order to obtain a complete picture
of a potential role of mtDNA in the formation and
expansion of this cancer, it would be necessary to per-
form whole mitochondrial genome sequencing, includ-
ing other cancer-related tissues (from recurrences,
distant metastases or margin). Such experiments should
also allow to further estimate the prognostic value of
data based on the D-loop sequence itself, and possibly
reveal some other potential risk factors, as it was the
case for G10398A in breast cancer among African
American-women [81]. Moreover, as the data were com-
pared with general mitochondrial databases [42,63], the
idea of comparison with the mtDNA sequences (D-loop
and coding region) from healthy Polish subjects would
also be valuable. Although acquiring a representative set
of such data is labour-intensive, in further perspective it
seems to be worth the effort.
Conclusions
Mitochondrial research may enable establishment of
bio-markers allowing the identification of individuals at
high risk for vulvar cancer and to develop screening
approaches and early diagnosis tools. Moreover, analysis
of mtDNA polymorphism (and possibly also mutational)
pattern may be used to selectp o p u l a t i o na ti n c r e a s e d
risk of cancer development, who should be enrolled in
extensive screening program. Molecular assessment of
mitochondrial abnormalities of cancer cells could repre-
sent a promising tool not only for prognosis and early
diagnosis of neoplasia, but possibly also during the fol-
low-up of cancer patients. If cost-effectiveness of mole-
cular techniques is considered. PCR seems to be the
optimal method for outpatient treatment regimens.
Additionally, the application of PCR-coupled with gel
electrophoresis or DNA sequencing may be used for
rapid analysis of multiple samples in hospital labora-
tories. In the clinical context, the high frequency of
mitochondrial genome instability, in combination with
PCR-based assays of high sensitivity, may be of potential
usefulness. In future studies related to cancer epidemiol-
ogy, the significance of a particular mtDNA polymorph-
ism(s) should be analyzed together with other
polymorphisms in mtDNA and in nuclear DNA.
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